ANI Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . ANI Pharmaceuticals
ANIP Stock  USD 64.22  0.13  0.20%   
ANI Pharmaceuticals financial statements provide useful quarterly and yearly information to potential ANI Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on ANI Pharmaceuticals financial statements helps investors assess ANI Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting ANI Pharmaceuticals' valuation are summarized below:
Gross Profit
364.2 M
Profit Margin
(0.03)
Market Capitalization
1.4 B
Enterprise Value Revenue
3.0238
Revenue
614.4 M
There are currently one hundred twenty fundamental signals for ANI Pharmaceuticals that can be evaluated and compared over time across rivals. Investors and active traders are advised to validate ANI Pharmaceuticals' prevailing fundamental performance against the performance between 2010 and 2025 to make sure the trends are evolving in the right direction. As of 03/19/2025, Market Cap is likely to grow to about 496.8 M, while Enterprise Value is likely to drop slightly above 43 M.

ANI Pharmaceuticals Total Revenue

645.09 Million

Check ANI Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ANI Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 71.1 M, Interest Expense of 18.5 M or Selling General Administrative of 262.1 M, as well as many indicators such as Price To Sales Ratio of 1.65, Dividend Yield of 0.0012 or PTB Ratio of 2.37. ANI financial statements analysis is a perfect complement when working with ANI Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of ANI Pharmaceuticals Correlation against competitors.
To learn how to invest in ANI Stock, please use our How to Invest in ANI Pharmaceuticals guide.

ANI Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets1.3 B1.3 B490.6 M
Slightly volatile
Other Current Liabilities138.7 M132.1 M43 M
Slightly volatile
Total Current Liabilities203.4 M193.7 M72.1 M
Slightly volatile
Total Stockholder Equity450 M428.5 M212.1 M
Slightly volatile
Property Plant And Equipment Net59.7 M56.9 M26.7 M
Slightly volatile
Accounts Payable47.9 M45.7 M14.7 M
Slightly volatile
Cash152.1 M144.9 M79.3 M
Slightly volatile
Non Current Assets Total793.8 M756 M269.8 M
Slightly volatile
Cash And Short Term Investments158.7 M151.2 M80.1 M
Slightly volatile
Common Stock Total Equity85590033.9 M
Slightly volatile
Common Stock Shares Outstanding20.3 M19.3 M11.2 M
Slightly volatile
Liabilities And Stockholders Equity1.3 B1.3 B490.6 M
Slightly volatile
Other Current Assets18.9 M18 M9.6 M
Slightly volatile
Total Liabilities897.9 M855.2 M278.5 M
Slightly volatile
Property Plant And Equipment Gross106.8 M101.7 M38 M
Slightly volatile
Total Current Assets554.1 M527.7 M220.8 M
Slightly volatile
Common Stock1.7 K1.8 K33.9 M
Slightly volatile
Other Stockholder Equity523.5 M498.6 M231.1 M
Slightly volatile
Short and Long Term Debt Total160.6 M315 M160.8 M
Slightly volatile
Short Term Debt8.7 M9.2 M32.6 M
Pretty Stable
Current Deferred Revenue39.2 M37.4 M14.9 M
Slightly volatile
Non Current Liabilities Total694.6 M661.5 M220.3 M
Slightly volatile
Net Receivables232.8 M221.7 M82.6 M
Slightly volatile
Long Term Debt Total114.2 M202.2 M125 M
Slightly volatile
Long Term Investments3.8 M3.9 M3.5 M
Slightly volatile
Property Plant Equipment52.2 M49.7 M25.7 M
Slightly volatile
Capital Surpluse237.5 M464.5 M220.8 M
Slightly volatile
Other Liabilities42.3 M40.3 M11.8 M
Slightly volatile
Short and Long Term Debt8.7 M9.2 M58.1 M
Slightly volatile
Deferred Long Term Asset Charges22.4 M32.2 M20.5 M
Slightly volatile
Net Invested Capital619.3 M1 B484.8 M
Slightly volatile
Capital Stock15.6 M28.6 M7.4 M
Slightly volatile
Warrants19.9 M22.4 M24.4 M
Slightly volatile

ANI Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization71.1 M67.7 M30.5 M
Slightly volatile
Selling General Administrative262.1 M249.6 M73.1 M
Slightly volatile
Total Revenue645.1 M614.4 M210.4 M
Slightly volatile
Other Operating Expenses644.5 M613.8 M206.4 M
Slightly volatile
Research Development46.8 M44.6 M18.3 M
Slightly volatile
Total Operating Expenses644.5 M613.8 M156 M
Slightly volatile
Discontinued Operations156 K175.5 K191.3 K
Slightly volatile
Non Recurring3.8 M5.2 M5 M
Pretty Stable
Interest Income13.7 M14.9 M12.3 M
Slightly volatile
Reconciled Depreciation52.7 M67.7 M39.5 M
Slightly volatile

ANI Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow232.2 M221.1 M77.5 M
Slightly volatile
Depreciation71.1 M67.7 M30.7 M
Slightly volatile
Capital Expenditures20.8 M17 M33.1 M
Very volatile
End Period Cash Flow152.1 M144.9 M81.1 M
Slightly volatile
Stock Based Compensation17.7 M29.3 M9.2 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.651.738221.3491
Slightly volatile
Dividend Yield0.00120.00157.0E-4
Slightly volatile
PTB Ratio2.372.4922.9389
Slightly volatile
Days Sales Outstanding101132148
Pretty Stable
Book Value Per Share22.522.182917.7687
Slightly volatile
Average Payables1.3 M2.5 M2.3 M
Slightly volatile
Stock Based Compensation To Revenue0.04540.04780.234
Slightly volatile
Capex To Depreciation0.260.282.3047
Slightly volatile
PB Ratio2.372.4922.9389
Slightly volatile
Inventory Turnover1.951.881.9758
Slightly volatile
Days Of Inventory On Hand184201211
Slightly volatile
Sales General And Administrative To Revenue0.240.252.0
Slightly volatile
Research And Ddevelopement To Revenue0.06890.07267.5656
Slightly volatile
Capex To Revenue0.04150.04370.4112
Slightly volatile
Cash Per Share7.437.82529.0176
Slightly volatile
Intangibles To Total Assets0.280.46880.3058
Slightly volatile
Current Ratio2.592.72455.2029
Slightly volatile
Receivables Turnover2.632.77092.5787
Pretty Stable
Shareholders Equity Per Share22.522.182917.7687
Slightly volatile
Debt To Equity0.610.7350.7185
Slightly volatile
Capex Per Share1.410.932.8442
Very volatile
Average Receivables35.3 K37.2 K359.2 K
Slightly volatile
Revenue Per Share33.3931.803314.2102
Slightly volatile
Interest Debt Per Share10.3217.216412.58
Slightly volatile
Debt To Assets0.290.24540.3487
Pretty Stable
Graham Number24.8528.0920.9976
Pretty Stable
Operating Cycle225132317
Pretty Stable
Price Book Value Ratio2.372.4922.9389
Slightly volatile
Company Equity Multiplier3.152.99562.0348
Slightly volatile
Long Term Debt To Capitalization0.470.41640.4289
Very volatile
Total Debt To Capitalization0.340.42360.4037
Slightly volatile
Debt Equity Ratio0.610.7350.7185
Slightly volatile
Quick Ratio1.922.01834.5353
Slightly volatile
Cash Ratio0.710.74793.211
Slightly volatile
Days Of Inventory Outstanding184201211
Slightly volatile
Days Of Sales Outstanding101132148
Pretty Stable
Price To Book Ratio2.372.4922.9389
Slightly volatile
Fixed Asset Turnover7.4310.80457.4365
Pretty Stable
Debt Ratio0.290.24540.3487
Pretty Stable
Price Sales Ratio1.651.738221.3491
Slightly volatile
Asset Turnover0.50.47860.3544
Slightly volatile
Price Fair Value2.372.4922.9389
Slightly volatile

ANI Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap496.8 M473.1 M400.7 M
Slightly volatile

ANI Fundamental Market Drivers

Forward Price Earnings10.0604
Cash And Short Term Investments151.2 M

ANI Upcoming Events

14th of March 2024
Upcoming Quarterly Report
View
13th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
14th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About ANI Pharmaceuticals Financial Statements

ANI Pharmaceuticals shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although ANI Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in ANI Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on ANI Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue37.4 M39.2 M
Total Revenue614.4 M645.1 M
Cost Of Revenue250.2 M262.7 M
Stock Based Compensation To Revenue 0.05  0.05 
Sales General And Administrative To Revenue 0.25  0.24 
Research And Ddevelopement To Revenue 0.07  0.07 
Capex To Revenue 0.04  0.04 
Revenue Per Share 31.80  33.39 

Additional Tools for ANI Stock Analysis

When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY